Oct 2 (Reuters) - Antisense Therapeutics Ltd (ANP) :
- Advised by FDA that full clinical hold for phase IIb clinical study of ATL1102 for multiple sclerosis has been lifted
- Co's application to conduct clinical trial of ATL1102 has been approved by Human Research Ethics Committee
News: ANP Antisense Therapeutics says FDA lifts hold for multiple sclerosis drug study
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.73M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 8.9¢ | 8.2¢ | $63.67K | 761.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 43210 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 200 | 1 |
View Market Depth
| Last trade - 15.59pm 10/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.4¢ |
Change
-0.001 ( 3.45 %) |
||||
| Open | High | Low | Volume | ||
| 8.9¢ | 8.9¢ | 8.2¢ | 115933 | ||
| Last updated 14.43pm 10/06/2024 ? | |||||
| PER (ASX) Chart |